nirmatrelvir

From Aaushi

Jump to navigation Jump to search

^[1]^[2]

Indications

used in combination with ritonavir in Paxlovid to treat early outpatient Covid-19

Mechanism of action

viral protease inhibitor
- expected in vitro activity against all clinically significant SARS-CoV-2 variants as of December 22, 2021

Notes

emergence of SARS-CoV-2 strains resistant to nirmatrelvir after treatment with Paxlovid is rare, independent of virologic rebound^[2]

More general terms

antiviral agent

Component of

Paxlovid (nirmatrelvir/ritonavir)

References

↑ McNamara D FDA Authorizes Pfizer Antiviral Pill for COVID-19. Medscape. December 22, 2021 https://www.medscape.com/viewarticle/965398
↑ ^2.0 ^2.1 Tamura TJ, Choudhary MC, Deo R et al Emerging SARS-CoV-2 Resistance After Antiviral Treatment. JAMA Netw Open. 2024 Sep 3;7(9):e2435431. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39320890 PMCID: PMC11425144 Free PMC article. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824050

Retrieved from "https://aaushi.info/w/index.php?title=A57430&oldid=1227508"

↑ Back to top